Pharmacology and Toxicology

Small-Molecule In Vitro Inhibitors of the Coronavirus Spike – ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

This article has 4 authors:
1. Damir Bojadzic
2. Oscar Alcazar
3. Jinshui Chen
4. Peter Buchwald
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Oct 22, 2020Latest activity Oct 26, 2020
In Vivo Pharmacokinetic Study of Remdesivir Dry Powder for Inhalation in Hamsters

This article has 8 authors:
1. Sawittree Sahakijpijarn
2. Chaeho Moon
3. Zachary N. Warnken
4. Esther Y. Maier
5. Jennie E. DeVore
6. Dale J. Christensen
7. John J. Koleng
8. Robert O. Williams
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Dec 23, 2020Latest activity Dec 27, 2020
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models

This article has 16 authors:
1. Yingjun Li
2. Liu Cao
3. Ge Li
4. Feng Cong
5. Yunfeng Li
6. Jing Sun
7. Yinzhu Luo
8. Guijiang Chen
9. Guanguan Li
10. Ping Wang
11. Fan Xing
12. Yanxi Ji
13. Jincun Zhao
14. Yu Zhang
15. Deyin Guo
16. Xumu Zhang
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Oct 27, 2020Latest activity Oct 30, 2020
A comparison of Remdesivir versus Au ₂₂ Glutathione ₁₈ in COVID-19 golden hamsters: a better therapeutic outcome of gold compound

This article has 22 authors:
1. Zhesheng He
2. Fei Ye
3. Chunyu Zhang
4. Jiadong Fan
5. Zhongying Du
6. Wencong Zhao
7. Qing Yuan
8. Wenchao Niu
9. Fuping Gao
10. Bo He
11. Peng Cao
12. Lina Zhao
13. Xuejiao Gao
14. Xingfa Gao
15. Bo Sun
16. Yuhui Dong
17. Jincun Zhao
18. Jianxun Qi
19. Huaidong Jiang
20. Yong Gong
21. Wenjie Tan
22. Xueyun Gao
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Oct 16, 2020Latest activity Oct 19, 2020
Losartan promotes cell survival following SARS-CoV-2 infection in vitro

This article has 7 authors:
1. Reza Nejat
2. Ahmad Shahir Sadr
3. Brendan T. Freitas
4. Jackelyn Crabtree
5. Scott D. Pegan
6. Ralph A. Tripp
7. David J. Najafi
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Dec 28, 2020Latest activity Dec 29, 2020
Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors

This article has 9 authors:
1. Mario Milani
2. Manuela Donalisio
3. Rafaela Milan Bonotto
4. Edoardo Schneider
5. Irene Arduino
6. Francesco Boni
7. David Lembo
8. Alessandro Marcello
9. Eloise Mastrangelo
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Nov 12, 2020Latest activity Nov 13, 2020
An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity

This article has 15 authors:
1. Naoya Kitamura
2. Michael Dominic Sacco
3. Chunlong Ma
4. Yanmei Hu
5. Julia Alma Townsend
6. Xiangzhi Meng
7. Fushun Zhang
8. Xiujun Zhang
9. Adis Kukuljac
10. Michael Thomas Marty
11. David Schultz
12. Sara Cherry
13. Yan Xiang
14. Yu Chen
15. Jun Wang
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Dec 20, 2020Latest activity Dec 21, 2020
Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens

This article has 18 authors:
1. Wei Jiang
2. Ailing Yang
3. Jingchuan Ma
4. Dawei Lv
5. Mingxian Liu
6. Liang Xu
7. Chao Wang
8. Zhengjin He
9. Shuo Chen
10. Jie Zhao
11. Shishuang Chen
12. Qi Jiang
13. Yankai Chu
14. Lin Shan
15. Zhaocai Zhou
16. Yun Zhao
17. Gang Long
18. Hai Jiang
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Oct 27, 2020Latest activity Oct 30, 2020
SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray

This article has 12 authors:
1. Krzysztof Pyrć
2. Aleksandra Milewska
3. Emilia Barreto Duran
4. Paweł Botwina
5. Rui Lopes
6. Alejandro Arenas-Pinto
7. Moutaz Badr
8. Ryan Mellor
9. Tammy L. Kalber
10. Delmiro Fernandes-Reyes
11. Andreas G. Schätzlein
12. Ijeoma F. Uchegbu
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Dec 10, 2020Latest activity Dec 11, 2020
Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation

This article has 7 authors:
1. Zhijian Xu
2. Cheng Peng
3. Yulong Shi
4. Zhengdan Zhu
5. Kaijie Mu
6. Xiaoyu Wang
7. Weiliang Zhu
Reviewed by ScreenIT

This article has 1 evaluationAppears in 1 listLatest version Jan 28, 2020Latest activity Aug 4, 2020

Previous Page 14 of 22 Next

Pharmacology and Toxicology

Small-Molecule In Vitro Inhibitors of the Coronavirus Spike – ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2

In Vivo Pharmacokinetic Study of Remdesivir Dry Powder for Inhalation in Hamsters

Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models

A comparison of Remdesivir versus Au ₂₂ Glutathione ₁₈ in COVID-19 golden hamsters: a better therapeutic outcome of gold compound

Losartan promotes cell survival following SARS-CoV-2 infection in vitro

Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors

An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity

Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens

SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray

Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation